A systematic review and meta-analysis evaluating two percutaneous ablation techniques – microwave ablation (MWA) and radiofrequency ablation (RFA) – showed that the former fared better than the latter in reducing local tumour progression (LTP) rates in individuals with hepatocellular carcinoma (HCC) and/or liver metastases.
The addition of pertuzumab to a trastuzumab-docetaxel regimen in the neoadjuvant setting improved total pathological complete response (tpCR) rates in Asian women with early or locally advanced ERBB2-positive breast cancer, according to the phase III PEONY trial from China.
Quality of life (QoL) in breast cancer patients worsens 2 years following diagnosis with different courses by treatment received, a study has found. Specifically, endocrine therapy exerts a major detrimental impact on QoL as opposed to chemotherapy having a transient negative effect in postmenopausal patients.
The addition of the fluoroquinolone levofloxacin to myeloma therapy during the first 12 weeks led to a significant reduction in febrile episodes and deaths compared with placebo, suggesting that levofloxacin prophylaxis could be a standard of care in the first 3 months following myeloma diagnosis to prevent infection, according to a British study.
The addition of radiofrequency ablation (RFA) or high-dose radiotherapy (RT) to accompany transcatheter arterial chemoembolization (TACE) may improve the overall survival rates of patients with hepatocellular carcinoma (HCC) versus TACE alone.